Trial Profile

A Phase 1b/2 Study To Evaluate The Efficacy, Safety, Pharmacokinetics And Pharmacodynamics Of EVER001 In Participants With Selected Proteinuric Glomerular Diseases

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 21 Sep 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Civorebrutinib (Primary)
Indications Membranous glomerulonephritis; Renal failure
Focus Adverse reactions; Proof of concept
Sponsors Everest Medicines

Most Recent Events

15 Sep 2026 Actual primary completion date changed from 22 Jul 2026 to 27 Jul 2026.
05 Aug 2026 Status changed from recruiting to completed.
26 Jun 2025 According to Everest Medicines media release, Latest results(as of March 21, 2025) from this trial will be presented at nephrology-focused key opinion leader (KOL) event on Monday, June 30, 2025 .

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com